Meeting
2020 ASCO Virtual Scientific Program
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
Authors
Cora N. Sternberg
Englander Institute of Precision Medicine, Weill Cornell Medicine, New York, NY
Cora N. Sternberg , Daniel Castellano , Johann S. De Bono , Karim Fizazi , Bertrand F. TOMBAL , Christian Wülfing , Gero Kramer , Jean-Christophe Eymard , Aristotelis Bamias , Joan Carles , Roberto Iacovelli , Bohuslav Melichar , Asgerdur Sverrisdottir , Christine Theodore , Susan Feyerabend , Carole Helissey , Elizabeth Poole , Ayse Ozatilgan , Christine Geffriaud-Ricouard , Ronald De Wit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02485691
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5559)
DOI
10.1200/JCO.2020.38.15_suppl.5559
Abstract #
5559
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edwin M. Posadas
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa